Trump's Pneumonia Aid Offer to Russia Serves U.S. Pharma Interests

Politologist Lyudmila Adilova, a professor at the Russian State University for the Humanities and a senior analyst at Moscow State University's Information and Analytical Center, suggests that U.S. President Donald Trump's recent offer to assist Russia with the spread of pneumonia in Irkutsk Oblast is driven by commercial interests rather than humanitarian concern. Speaking to Pravda. Ru, the expert argued that Washington's gesture is calculated to open new markets for major American businesses and alter the geopolitical balance. Previously, during an official briefing, Trump stated that the White House was closely monitoring the outbreak of pneumonia of unknown etiology in the Siberian region and was prepared to offer support to the extent possible. Adilova characterized this as a typical pragmatic move for a leader with a background in business, asserting that Trump acts on behalf of transnational pharmaceutical corporations that view epidemiological threats as opportunities for expansion. She noted that the U.S. is simultaneously advancing its own biological initiatives, including large-scale programs aimed at reducing populations of dangerous infection carriers to protect its own population. "Trump does nothing without a reason-he is a businessman, so there must be a benefit for him. I believe he wants to shift responsibility for the situation onto China and create a negative atmosphere in relations between Russia and China: turning friendly ties into unfriendly ones, and possibly hostile ones,” she said.